Trivalent flu shots didn’t drop the ball: what the 2025-26 switch really meant for protection this season

If you heard that the 2025-26 flu shot covered fewer strains than older flu vaccines, you may have wondered if people got a lesser product this season.

The best-supported answer is no.

By the 2025-26 U.S. flu season, all flu vaccines were trivalent, meaning they targeted three flu virus groups instead of four. That change did not mean people lost protection against an important flu strain that was actively spreading. The missing strain, called influenza B/Yamagata, has not been confirmed in natural circulation since March 2020, according to the World Health Organization. What seems to have mattered more this season was something else: the viruses that did circulate, especially H3N2, changed enough after vaccine strain selection to make the match less ideal.

What changed with flu vaccines this season?

For the 2025-26 season, the Centers for Disease Control and Prevention said all U.S. flu vaccines were trivalent. In plain language, that means they were designed to protect against:

one influenza A(H1N1) virus
one influenza A(H3N2) virus
one influenza B virus from the B/Victoria lineage

Older quadrivalent flu shots included one more influenza B component: B/Yamagata.

It is also worth clearing up the timing. The U.S. move away from quadrivalent vaccines actually began for the 2024-25 season. By 2025-26, trivalent was no longer a new experiment. It was the standard U.S. seasonal flu formula.

Why was B/Yamagata removed?

The short version is that public health agencies no longer considered B/Yamagata a meaningful part of real-world seasonal flu circulation.

In its transition FAQ, the World Health Organization said including a B/Yamagata antigen was no longer warranted because naturally occurring B/Yamagata viruses had not been confirmed after March 2020. A review published in Lancet Microbe went a step further and described B/Yamagata as probably extinct or functionally disappeared from circulation.

That does not prove B/Yamagata can never return. Science rarely works in absolutes, and experts have been careful not to claim that. But the available surveillance evidence supports a practical conclusion: keeping that fourth component in routine seasonal flu shots was no longer expected to add meaningful protection for most people.

So why did the flu shot look weaker in 2025-26?

This is the key point for readers: the season’s lower vaccine effectiveness does not appear to be explained by the switch to trivalent vaccine.

In March 2026, CDC published an interim vaccine-effectiveness report in MMWR based on a test-negative case-control study across three U.S. surveillance networks. The analysis included 142,494 medical encounters from September 2025 through February 2026. That is an observational design, not a randomized trial, so the estimates can still shift by the end of the season. But it is the main real-world snapshot we have right now.

CDC pointed to a more likely reason for the weaker performance: drifted circulating viruses. Most subtyped influenza A viruses this season were H3N2, and most of those belonged to an antigenically drifted subclade called subclade K that emerged after vaccine strain selection. CDC also said many sequenced influenza B viruses differed from the season’s B vaccine component.

In other words, the bigger problem was virus mismatch among strains that were circulating, not the absence of a B/Yamagata strain that has not been confirmed in natural circulation for years.

What protection did the shot still provide?

Even in a rougher season, the flu shot still helped.

CDC’s interim estimates found that among children and adolescents, vaccine effectiveness was about 38% to 41% against flu-related outpatient visits and 41% against hospitalization. Among adults, it was about 22% to 34% against outpatient visits and 30% against hospitalization.

Those numbers can sound disappointing if you expect a flu shot to stop every infection. But that is not what flu vaccine effectiveness usually means. In this kind of study, it means vaccinated people had lower odds of needing medical care for lab-confirmed flu than similar unvaccinated people.

For many families, that practical difference matters more than the label on the vaccine. A shot that lowers the chance of an urgent care visit, emergency visit, or hospital stay is still doing important work, especially in a season dominated by H3N2, which is often harder on older adults.

Who should care most about that protection?

Lower-VE seasons can still be consequential for people at higher risk of severe flu, including:

adults 65 and older
young children, especially under 5
pregnant people
people with chronic heart, lung, kidney, or metabolic conditions
people with weakened immune systems

For these groups, even partial protection can mean a milder illness or avoiding hospitalization.

It is also why vaccination is only one layer of protection. If you develop flu symptoms such as fever, chills, cough, sore throat, body aches, or unusual fatigue, it is worth contacting a clinician promptly if you are high risk. Antiviral treatment works best when started early.

Does trivalent look like a one-season change or the new normal?

Right now, trivalent looks like the ongoing standard.

In March 2026, the Food and Drug Administration again recommended a three-strain composition for the 2026-27 U.S. influenza season: two influenza A viruses and one influenza B/Victoria virus. That reinforces that trivalent is not being treated as a temporary downgrade. It is the seasonal formula regulators expect manufacturers to keep using unless surveillance shows a real reason to change course.

What this means for readers

If you came away from this season thinking, “The flu shot was weaker because they took something out,” the evidence does not really support that conclusion.

The better takeaway is this:

Trivalent flu vaccines are not a cut-rate version of the flu shot.
The removed B/Yamagata component was dropped because it has not been confirmed in natural circulation since March 2020.
This season’s weaker protection is more plausibly linked to drifted H3N2 and some B viruses than to the trivalent formula itself.
Even in a lower-effectiveness season, vaccination still reduced medically attended flu and hospitalization.

That does not mean flu shots are perfect, and it does not mean every season will look the same. Final end-of-season estimates could still change. But based on what CDC, FDA, WHO, and the current literature show, Americans were not left meaningfully exposed just because the vaccine moved from four strains to three.

For most readers, the simplest conclusion is still the most useful one: trivalent flu vaccine remains a legitimate flu shot, not a lesser one.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.